Touchlight joins forces with University of Liverpool for NSCLC vaccine
04 Apr 2024
VaccinePhase 1ImmunotherapymRNA
Preview
Source: Pharmaceutical Technology
The Phase I trial will enrol 10 patients at the Clatterbridge Cancer CentreCancer Centre in Liverpool, shown above, and is funded by the UK’s Medical Research Council. Credit: John B Hewitt via Shutterstock.
UK-based CDMO Touchlight has teamed up with the University of Liverpool, UK, to utilise its doggybone DNA (dbDNA) technology in for developing a personalised DNA vaccine for patients with non-small cell lung cancer (NSCLC), which will be assessed in a clinical trial.
Touchlight’s dbDNA is a small, closed loop of DNA that is made in a lab using enzymes. This technique can speed up the drug development process by amplifying long and complex DNA sequences without traditional methods like bacterial fermentation.
The term doggybone DNA refers to the structure of the synthesised DNA molecule, which resembles a bone with two loops at each end. The approach offers a way to make vaccines very quickly, especially for personalised treatments. In March 2023, Touchlight received a £14m ($17.7m) grant from the UK government for commercial scale manufacturing of the technology.
A team at the University of Liverpool will use Touchlight’s dbDNA technology to develop a fully personalised therapeutic neoantigen DNA vaccine for NSCLC patients. Neoantigens are naturally occurring proteins found on the surface of cancer cells that train the immune system to recognise and fight abnormal lung cells.
Funded by the UK’s Medical Research Council, the Phase I trial will accrue 10 patients at the Clatterbridge Cancer CentreCancer Centre. The first patients are expected to be enrolled in the second half of 2024.
See Also:
England’s MMR vaccinations up 23% following NHS initiative
Preview
Source: Pharmaceutical Technology
Zoetis gets grant for recombinant viral vectors for multivalent pathogen protection in vaccines
Preview
Source: Pharmaceutical Technology
NSCLC is the most common form of lung cancer, affecting the cells that line the lungs. It differs from small cell lung cancer in cell size and appearance under a microscope. In the eight major markets (US, France, Germany, Italy, Spain, UK, Japan, and urban China), the number of NSCLC cases is expected to reach 1,463,151 in 2032, according to GlobalData.
GlobalData is the parent company of Pharmaceutical Technology.
This partnership adds to other recent developments involving the development of vaccines for treating lung cancer. In March, Cancer Research UK and the CRIS [Cancer Research Innovation in Science] Cancer Foundation awarded a £1.7m ($2.1m) grant to researchers at the University of Oxford, the Francis Crick Institute and University College London to develop LungVax, a neoantigen DNA vaccine for lung cancer patients.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.